20878583|t|American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
20878583|a|The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).
20878583	297	321	(S)-adenosylhomocysteine	Chemical	MESH:D012435
20878583	323	327	AHCY	Chemical	MESH:D012435
20878583	361	380	Alzheimer's disease	Disease	MESH:D000544
20878583	382	407	2,4-diphenyl-1H-imidazole	Chemical	-
20878583	431	434	CB2	Gene	1269
20878583	465	469	pain	Disease	MESH:D010146
20878583	471	490	checkpoint kinase 1	Gene	1111
20878583	492	496	Chk1	Gene	1111
20878583	502	517	Aurora kinase B	Gene	9212
20878583	545	551	cancer	Disease	MESH:D009369
20878583	563	580	pyridylmethylthio	Chemical	-
20878583	596	602	VEGFR2	Gene	3791
20878583	619	633	Janus kinase 2	Gene	3717
20878583	635	639	JAK2	Gene	3717
20878583	662	690	myeloproliferative disorders	Disease	MESH:D009196
20878583	732	743	L-002259713	Chemical	-
20878583	758	766	AZD-1480	Chemical	MESH:C545606
20878583	782	789	CYT-387	Chemical	MESH:C546012
20878583	811	822	ruxolitinib	Chemical	MESH:C540383
20878583	Association	MESH:D009369	1111
20878583	Negative_Correlation	MESH:D012435	MESH:D000544
20878583	Association	MESH:D010146	1269
20878583	Association	MESH:D009369	9212
20878583	Negative_Correlation	MESH:D012435	1111
20878583	Association	MESH:D009196	3717

